UNSPSC 51385004: Zomepirac sodium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H13ClNO3.Na.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y0185WZ209, chemically known as 5-(4-chlorobenzoyl)-1,4-dimethyl-1h-pyrrole-2-acetic acid but more generally known as zomepirac sodium, which bears US NIH Compound Identifier 5733. European Medicines Agency schedules Zomepirac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05193MIG.

Most nations, for tariff and trade purposes, schedule zomepirac sodium under HS 29339990 and SITC 51577. As of Q4 2014, ZOMEPIRAC SODIUM remains US FDA's Preferred Term for this commodity. Zomepirac sodium bears US NLM identifiers UMLS ID C0149477 and NCI Concept Code C62001. SMILES: CC1CC(N(C1C(=O)C2CCC(CC2)CL)C)CC(=O)[O-].O.O.[NA+].

UNSPSC 51385004 Zomepirac sodium is a Commodity code nominally identifying a specific nonsteroidal anti-inflammatory drug, but recent state and local procurement activity under this code does not reflect purchases of zomepirac specifically. Instead, the code tags pharmaceutical procurement at the state and local level more broadly — including naloxone distribution, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs. State and local issuing bodies using this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Purchasing is driven by public health initiatives, pharmacy benefit program management, and supply-chain cost optimization. The scope spans both emergency-response medications (naloxone for opioid overdose) and routine pharmaceutical distribution through authorized wholesaler networks, with vendors typically required to maintain current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, and substantial commercial general liability insurance.

Recent activity appears concentrated in Florida and Minnesota, with broader multistate coordination through cooperative purchasing vehicles. Seminole County, Florida issued an IFB (No. IFB60459723LAS) due July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a two-year initial term and one-year renewal option. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted an RFP (No. S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, with awarded vendors required to distribute through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, and pricing evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for establishing direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers outside traditional PBM and GPO arrangements.